Cidara Therapeutics, Inc.

11.75 USD
-1.26 (-9.68%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cidara Therapeutics, Inc. stock is down -2.89% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30% of the previous 9 July’s closed higher than June. 100% of analysts rate it a buy.

About Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc. focuses on the discovery, development, and commercialization of long-acting anti-infectives. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis.